IL268245A - Calichamycin derivatives and their conjugates with antibodies - Google Patents

Calichamycin derivatives and their conjugates with antibodies

Info

Publication number
IL268245A
IL268245A IL268245A IL26824519A IL268245A IL 268245 A IL268245 A IL 268245A IL 268245 A IL268245 A IL 268245A IL 26824519 A IL26824519 A IL 26824519A IL 268245 A IL268245 A IL 268245A
Authority
IL
Israel
Prior art keywords
drug conjugates
antibody drug
calicheamicin derivatives
calicheamicin
derivatives
Prior art date
Application number
IL268245A
Other languages
English (en)
Hebrew (he)
Inventor
Khaled Ahmad Omar
Paul Brown Stephen
John Dirico Kenneth
Dushin Russell
Frederick Filzen Gary
Puthenveetil Sujiet
Strop Pavel
Subramanyam Chakrapani
N Tumey Lawrence
Original Assignee
Pfizer
Khaled Ahmad Omar
Paul Brown Stephen
John Dirico Kenneth
Dushin Russell
Frederick Filzen Gary
Puthenveetil Sujiet
Strop Pavel
Subramanyam Chakrapani
N Tumey Lawrence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Khaled Ahmad Omar, Paul Brown Stephen, John Dirico Kenneth, Dushin Russell, Frederick Filzen Gary, Puthenveetil Sujiet, Strop Pavel, Subramanyam Chakrapani, N Tumey Lawrence filed Critical Pfizer
Publication of IL268245A publication Critical patent/IL268245A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL268245A 2017-01-24 2019-07-24 Calichamycin derivatives and their conjugates with antibodies IL268245A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449839P 2017-01-24 2017-01-24
PCT/IB2018/050153 WO2018138591A1 (en) 2017-01-24 2018-01-10 Calicheamicin derivatives and antibody drug conjugates thereof

Publications (1)

Publication Number Publication Date
IL268245A true IL268245A (en) 2019-09-26

Family

ID=61168135

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268245A IL268245A (en) 2017-01-24 2019-07-24 Calichamycin derivatives and their conjugates with antibodies

Country Status (14)

Country Link
US (2) US11993625B2 (cg-RX-API-DMAC10.html)
EP (1) EP3573995A1 (cg-RX-API-DMAC10.html)
JP (1) JP7078405B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190111086A (cg-RX-API-DMAC10.html)
CN (1) CN110461860A (cg-RX-API-DMAC10.html)
AU (1) AU2018211561B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019015069A2 (cg-RX-API-DMAC10.html)
CA (1) CA3051038C (cg-RX-API-DMAC10.html)
IL (1) IL268245A (cg-RX-API-DMAC10.html)
MX (1) MX2019008773A (cg-RX-API-DMAC10.html)
RU (1) RU2732568C1 (cg-RX-API-DMAC10.html)
SG (1) SG11201906414VA (cg-RX-API-DMAC10.html)
TW (1) TWI687221B (cg-RX-API-DMAC10.html)
WO (1) WO2018138591A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3573995A1 (en) * 2017-01-24 2019-12-04 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
EP3720504A1 (en) * 2017-12-06 2020-10-14 Synaffix B.V. Enediyne conjugates
EP3976112A1 (en) * 2019-06-03 2022-04-06 Synaffix B.V. Acetal-based cleavable linkers
GB2585102B (en) 2019-10-09 2021-06-30 Audio Inventions Ltd System for identification of a note played by a musical instrument
WO2025151608A1 (en) * 2024-01-10 2025-07-17 Systimmune, Inc. Connecting units for ligand-drug conjugates and methods of making and using thereof
WO2026050757A2 (en) * 2024-08-30 2026-03-05 ALX Oncology Inc. Calicheamicin derivatives and antibody-drug conjugates thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0313874B1 (en) * 1987-10-30 1994-04-13 American Cyanamid Company Disulfur analogs of LL-E33288 antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
WO2005009882A1 (en) * 2003-06-27 2005-02-03 Otis Elevator Company Absolute positioning system for elevators using dual encoders
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
JP6055404B2 (ja) * 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
SG186451A1 (en) 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
MX340090B (es) 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
US9453508B2 (en) 2013-02-25 2016-09-27 Asmo Co., Ltd. Electric oil pump and hydraulic pressure supply device
KR101614151B1 (ko) 2014-07-01 2016-04-22 한국화학연구원 흡입 독성 시험용 폐 모델 장치
HUE049325T2 (hu) 2014-08-28 2020-09-28 Pfizer Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック， インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
WO2017172907A1 (en) 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
WO2018069851A2 (en) 2016-10-11 2018-04-19 Sorrento Therapeutics, Inc. C-met antibody drug conjugate
EP3573995A1 (en) * 2017-01-24 2019-12-04 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof

Also Published As

Publication number Publication date
JP2018123122A (ja) 2018-08-09
RU2732568C1 (ru) 2020-09-21
TW201838632A (zh) 2018-11-01
BR112019015069A2 (pt) 2020-03-03
KR20190111086A (ko) 2019-10-01
WO2018138591A1 (en) 2018-08-02
US11993625B2 (en) 2024-05-28
AU2018211561A1 (en) 2019-07-18
US20240409573A1 (en) 2024-12-12
CN110461860A (zh) 2019-11-15
MX2019008773A (es) 2019-09-18
US20190345186A1 (en) 2019-11-14
CA3051038C (en) 2022-07-26
JP7078405B2 (ja) 2022-05-31
SG11201906414VA (en) 2019-08-27
TWI687221B (zh) 2020-03-11
EP3573995A1 (en) 2019-12-04
AU2018211561B2 (en) 2020-04-30
CA3051038A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
ZA201900059B (en) Anti-b7-h3 antibodies and antibody drug conjugates
IL265309A (en) Bispecific antibodies against MUC16 and CD3 and drug conjugates against MUC16
IL268102A (en) Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate
IL267003A (en) Multidrug antibody conjugates
PT3626825T (pt) Anticorpo anti-cdh6 e conjugado anticorpo anti-cdh6-fármaco
SG11202011159QA (en) Anti-mesothelin antibody and antibody drug conjugate thereof
IL274650A (en) Conjugate an antibody drug against CD40
IL251938A0 (en) Antibodies against CS1 and antibody-drug conjugates
IL287938A (en) Drug antibody conjugates
PL3941946T4 (pl) Przeciwciała klaudyny-6 i koniugat lekowy
IL265362A (en) Anti-c-met antibodies and drug conjugates containing such antibodies
EP3612567C0 (en) ANTI-VTCN1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
IL266112A (en) Antibodies against edb and antibody-drug conjugates
LT3380122T (lt) Antikūnai prieš 5t4 ir antikūno-vaistų konjugatai
SI3544634T1 (sl) Konjugati zdravila s protitelesom proti met
EP3601360A4 (en) ANTI-TMEFF1 ANTIBODIES AND ANTIBODY ACTIVE INGREDIENT CONJUGATES
EP3675908A4 (en) ANTI-EGFR-DRUG (ADC) ANTIBODY CONJUGATES AND ASSOCIATED USES
PT3380122T (pt) Anticorpos anti-5t4 e conjugados anticorpos fármaco